Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$3.21 +5.6%	$2.95	$0.40 ▼ $5.48	$71.57M	0.27	185,484 shs	143,490 shs
DERM Journey Medical	$7.47 +5.5%	$7.16	$3.54 ▼ $8.90	$164.93M	0.8	188,629 shs	239,603 shs
EPRX Eupraxia Pharmaceuticals	$5.28 +1.5%	$5.21	$2.20 ▼ $6.20	$187.17M	1.5	11,043 shs	3,916 shs
TRDA Entrada Therapeutics	$6.14 +4.6%	$6.38	$4.93 ▼ $21.79	$223.28M	-0.12	279,909 shs	198,835 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+5.59%	-2.73%	+4.56%	+179.13%	+339.30%
DERM Journey Medical	+5.51%	+7.48%	+1.08%	+6.71%	+69.77%
EPRX Eupraxia Pharmaceuticals	+1.54%	-0.75%	+2.64%	+36.43%	+97.75%
TRDA Entrada Therapeutics	+4.60%	+16.51%	-3.91%	-18.13%	-62.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.3024 of 5 stars	0.0	3.0	1.6	0.8	0.0
DERM Journey Medical	1.6272 of 5 stars	3.2	1.0	2.3	0.8	0.6
EPRX Eupraxia Pharmaceuticals	1.9642 of 5 stars	3.6	1.0	1.5	0.0	0.6
TRDA Entrada Therapeutics	3.0876 of 5 stars	3.5	3.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
DERM Journey Medical	2.33	Hold	$11.75	57.30% Upside
EPRX Eupraxia Pharmaceuticals	3.17	Buy	$11.00	108.33% Upside
TRDA Entrada Therapeutics	3.00	Buy	$25.67	318.02% Upside

Current Analyst Ratings Breakdown

Latest ABVC, DERM, TRDA, and EPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/15/2025	DERM Journey Medical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/13/2025	DERM Journey Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $13.00
8/8/2025	TRDA Entrada Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/24/2025	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	148.16	N/A	N/A	$0.40 per share	8.03
DERM Journey Medical	$56.13M	3.10	N/A	N/A	$0.83 per share	9.00
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	($0.30) per share	N/A
TRDA Entrada Therapeutics	$210.78M	1.11	$1.66 per share	3.70	$9.98 per share	0.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.17	N/A	∞	N/A	-963.46%	-46.76%	-23.02%	N/A
DERM Journey Medical	-$14.67M	-$0.38	N/A	N/A	N/A	-15.49%	-48.69%	-11.26%	11/11/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.85	N/A	N/A	N/A	N/A	-367.73%	-126.38%	11/6/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	-$1.78	N/A	N/A	N/A	-92.30%	-17.81%	-14.55%	11/4/2025 (Estimated)

Latest ABVC, DERM, TRDA, and EPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ABVC ABVC BioPharma	N/A	-$0.13	N/A	-$0.13	N/A	N/A
8/12/2025	Q2 2025	DERM Journey Medical	-$0.07	-$0.16	-$0.09	-$0.16	$14.93 million	$15.01 million
8/12/2025	Q2 2025	EPRX Eupraxia Pharmaceuticals	-$0.21	-$0.26	-$0.05	-$0.26	N/A	N/A
8/6/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	-$1.04	-$0.18	-$1.04	$8.17 million	$1.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.42	0.42
DERM Journey Medical	1.11	1.27	0.95
EPRX Eupraxia Pharmaceuticals	N/A	8.72	8.72
TRDA Entrada Therapeutics	N/A	18.64	18.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
DERM Journey Medical	7.25%
EPRX Eupraxia Pharmaceuticals	N/A
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
DERM Journey Medical	15.03%
EPRX Eupraxia Pharmaceuticals	N/A
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	23.54 million	14.08 million	Not Optionable
DERM Journey Medical	90	23.30 million	19.80 million	N/A
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
TRDA Entrada Therapeutics	110	38.04 million	34.95 million	Optionable

ABVC, DERM, TRDA, and EPRX Headlines

Recent News About These Companies

Connor Clark & Lunn Investment Management Ltd. Sells 74,068 Shares of Entrada Therapeutics, Inc. $TRDA

August 23 at 4:15 AM | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives $25.67 Average Target Price from Analysts

August 18, 2025 | americanbankingnews.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Rating of "Buy" from Brokerages

August 17, 2025 | marketbeat.com

Roth Capital Has Pessimistic Outlook of TRDA Q3 Earnings

August 12, 2025 | americanbankingnews.com

What is William Blair's Forecast for TRDA Q3 Earnings?

August 12, 2025 | americanbankingnews.com

Entrada (TRDA) Q2 Revenue Drops 98%

August 11, 2025 | theglobeandmail.com

HC Wainwright Issues Pessimistic Outlook for TRDA Earnings

August 11, 2025 | marketbeat.com

Roth Capital Issues Pessimistic Forecast for TRDA Earnings

August 11, 2025 | marketbeat.com

William Blair Issues Negative Forecast for TRDA Earnings

August 11, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

August 9, 2025 | finance.yahoo.com

Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

August 6, 2025 | globenewswire.com

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?

July 31, 2025 | zacks.com

5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

July 13, 2025 | investing.com

Entrada therapeutics (TRDA) director Parmar sells $202k in stock

July 13, 2025 | investing.com

Ventures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 12, 2025 | insidertrades.com

Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

July 3, 2025 | investing.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 Shares

July 2, 2025 | insidertrades.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC, DERM, TRDA, and EPRX Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$3.21 +0.17 (+5.59%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.25 +0.04 (+1.25%)

As of 08/22/2025 07:59 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Journey Medical NASDAQ:DERM

$7.47 +0.39 (+5.51%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.49 +0.02 (+0.27%)

As of 08/22/2025 04:10 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.28 +0.08 (+1.54%)

Closing price 08/22/2025 03:50 PM Eastern

Extended Trading

$5.52 +0.25 (+4.64%)

As of 08/22/2025 07:42 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Entrada Therapeutics NASDAQ:TRDA

$6.14 +0.27 (+4.60%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.14 +0.00 (+0.08%)

As of 08/22/2025 04:10 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time